Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reactogenicity & Immunogenicity Study of Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Co-administered With Either OPV or IPV in Healthy Infants (Approximately 5-10 Weeks Old) in South Africa

NCT00346892 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00346892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00346892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reactogenicity & Immunogenicity Study of Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Co-administered With Either OPV or IPV in Healthy Infants (Approximately 5-10 Weeks Old) in South Africa
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2001
Completion date
Not reported
Enrollment
450
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rotavirus infections